Antibacterial Drug Market to Grow at 3.97% CAGR reaching $35.6 billion by 2022
Apr 20, 2017
The Global Antibacterial Drugs Market to 2022 report considers the key developments with particular focus on drugs indicated for use in pneumonia, methicillin-resistant staphylococcus aureus (MRSA), sepsis and tuberculosis. The Antibacterial Drug Market report predicts market size, in-depth multi-scenario market forecast and company analysis.
Pune, India - April 20, 2017 /MarketersMedia/ —
The antibacterial drug market covers the drugs used in the prophylaxis and treatment of bacterial infections. With a growing global concern over antimicrobial resistance and its progressive growth, there is a pronounced need for innovation within this market.
Browse 27 Tables and 76 Figures, 10 Companies Spread across 177 pages is available @ http://www.reportsnreports.com/contacts/discount.aspx?name=956399 .
Company Analysis Profiled are Pfizer, GlaxoSmithKline, Merck & Co, Allergan, Cempra, Insmed, Otsuka, Roche, Bayer and AstraZeneca.
The report, Global Antibacterial Drugs Market to 2022 - Vaccines Retain Market Prominence While Pipeline Offers Innovative Approaches to Tackling Antimicrobial Resistance, states that emerging companies and the approvals of new products will drive this growth, along with the continued success of the established marketed products Infanrix, which vaccinates against diphtheria, tetanus and pertussis, and Augmentin, which is amoxicillin sodium and clavulanate potassium.
The antibacterial market is currently dominated by vaccines, in particular those for the prevention of pneumococcal infections, diphtheria, tetanus and pertussis. However, recent years have seen key additions in the form of therapies for antibiotic-resistant bacteria, including strains with multi-drug resistance. The number of such products is expected to increase drastically between 2016 and 2022. Drugs for the prevention of bacterial infections are typically vaccines, which help to train the body's immune system to fight off specific infections, and can therefore help to prevent infections of certain bacterial strains. However, several prophylactic monoclonal antibodies are also currently in development.
Drugs for the treatment of bacterial infections are slightly more varied. Most common are beta-lactam antibiotics, which include the very widely prescribed penicillin. However, bacteria have developed resistance to penicillin by producing beta-lactamase enzymes that break open the beta-lactam ring found in these antibiotics, rendering them ineffective. As a result modern beta-lactams are frequently combination drugs of a beta-lactam and a beta-lactamase inhibitor.
Order a Copy of Report @ http://www.reportsnreports.com/purchase.aspx?name=956399 .In addition to beta-lactams there are several other classes of drugs used to treat bacterial infections. These include fluoroquinolones, which inhibit DNA gyrase and/or topoisomerase IV; and protein synthesis inhibitors, which have applications within the treatment of bacteria that are resistant to beta-lactam antibiotics. However, bacterial resistance has also developed against these drugs, and as such there is a gap in the market for a new generation of drugs that are effective against drug-resistant bacteria.
Scope
Antibiotic resistance has caused a surge in the development of antibiotics:
• How big is the antibiotic pipeline?
• How are companies attempting to overcome antibiotic resistance?
The Antibacterial Drug Market is forecast to rise from around $27.1 billion in 2015 to $35.6 billion in 2022:
• How much will the approval of new products and the patent expiries of existing ones contribute to this market growth?
• Will vaccines continue to drive market revenue?
The pipeline contains a range of molecular targets:
• Which molecular targets are most popular in the current pipeline?
• How many late-stage products are active against drug-resistant bacteria?
• What are the commercial prospects for the most promising late-stage pipeline products?
Big Pharma maintains a strong presence within the antibacterial drug market:
• Which of the leading companies are expected to have the highest share of the market by 2022?
• Which of the leading pharmaceutical companies are expected to bring new products to market during the forecast period?
• Which companies rely heavily of revenues derived from antibacterial drugs?
Table of Contents
Introduction
Key Marketed Products
Pipeline Landscape Assessment
Multi-Scenario Market Forecast to 2022
Company Analysis and Positioning
Strategic Consolidations
About Us
ReportsnReports.com is single source for all market research needs. Our database includes 500,000+ market research reports from over 95 leading global publishers & in-depth market research studies of over 5000 micro markets.
Contact Info:
Name: Ritesh Tiwari
Email: [email protected]
Organization: ReportsnReports.com
Address: Magarpatta City, Pune, Maharashtra, India
Phone: +1-888-391-5441
For more information, please visit http://www.reportsnreports.com/reports/956399-global-antibacterial-drugs-market-to-2022-vaccines-retain-market-prominence-while-pipeline-offers-innovative-approaches-to-tackling-antimicrobial-resistance.html
Source: MarketersMedia
Release ID: 188039
More News
Weight Loss Drugs Give Restaurants a New Hurdle: Diners Who Eat Less
Fewer orders and higher costs are squeezing restaurants big and small as people on the weight-loss drugs eat and drink less when dining out.
Tech giants' AI boom faces a rising cash-flow test
The fiscal 2026 earnings cycle has underscored the extraordinary momentum behind the AI boom, with tech giants posting record revenues while their shares have also rallied. But beneath the headline numbers, a new test is emerging: how long can AI-driven cash generation keep pace with the massive investment required to expand computing capacity?
Trump Says Economy Has ‘Public Relations’ Problem Amid High Prices and Slow Hiring
The president, who had hoped to tout a growing economy on the campaign trail, has found it hard to break through as workers’ wages fail to keep up.
Suppliers pile pressure on government over energy bills
Immediate action is needed to help households struggling with bills this winter, says trade body Energy UK.
America Wants to Make More Generic Drugs. India Shows Why That’s Hard.
Cheap labor and global supply chains are among the obstacles to President Trump’s plan to bring generic drug manufacturing back home.
New baby bank 'open to everybody'
The facility offers essential items for free, including clothes for babies and small children.
Rising energy costs add to cost of living for Northern Ireland's consumers
Households across Northern Ireland face increasing pressure on the cost of living as energy price hikes have come into effect.
G7 to release millions of barrels of oil and diesel after Trump threat
The co-ordinated release is aimed at heading off further price spikes and avoiding a ban on US diesel exports.
White House Filing Claims President Has Authority to Bar News Outlets
The Trump administration again defended the decision to bar CNN, MS NOW and Politico from the White House and to exclude journalists from the pool that covers the president in small spaces.
Federal Watchdog Investigates Adam Kinzinger for Kalshi Bets on His Pardon
The inquiry by the Commodity Futures Trading Commission centers on bets the former congressman made on Kalshi in the weeks before he was pardoned in January 2025.
US Sanctions A7, a Russia Firm That Helps Sidestep Economic Restrictions
The move followed reports detailing how A7, a Moscow firm, uses shell companies around the world to move funds for clients who are themselves subject to sanctions.
G20 trade ministers meet in Wisconsin amid trade tensions
G20 trade ministers meet in Wisconsin amid trade tensions
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.